Principal Investigator:
Christina Boull, MD
University of Minnesota
Overview:
This is a multi-center retrospective chart review of pediatric patients who have received MEK inhibitors and/or BRAF inhibitors to better document and describe the associated cutaneous changes. The use of targeted therapies in the MAP kinase pathway for cancer treatment is increasing and it is essential to anticipate and prevent associated skin toxicities to prevent interruption of these cancer therapies.
Status:
Analyzing data.